Keywords: acute interstitial nephritis; corticosteroids; fluindione Drug-induced acute interstitial nephritis (AIN) is an established cause of acute kidney injury (AKI). Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequent offending drugs [1] . Only a few vitamin K antagonist-induced AIN cases have been reported. Some publications describe AIN associated with fluindione (Previscan R ), an anticoagulant of the antivitamin K family, derived from indanedione, exclusively marketed in France. We present an additional case of AIN secondary to fluindione and review the available literature.
diagnosis of fluindione-induced AIN (FI-AIN) was made. Despite withdrawal of the offending agent replaced by acenocoumarol, and oral corticosteroid therapy (1 mg/kg/day), renal function did not return to baseline values after 1 month (SCr, 259.6 µmol/L) but improved to 199.8 µmol/L 6 months later.
About 15% of the renal biopsies performed on patients with AKI demonstrate drug-induced AIN as the cause of the renal insufficiency. Only 13% of these patients showed the classic triad of rash, fever and eosinophilia. Discontinuation of the offending drug remains the first therapeutic step. Nevertheless, a considerable part of the affected patients may develop ESRD (23.4%). An important clinical prognostic factor is the average duration of the renal dysfunction; a cut-off point of 2-3 weeks seems relatively determining [1] [2] [3] .
Few cases of vitamin K antagonist-induced AIN have been reported with warfarin, phenindione and fluindione [4] . Hypersensitivity reactions occur in 0.2-2% of cases [5] . Review of the literature revealed 16 biopsy-proven FI-AIN [5] [6] [7] [8] [9] [10] [11] , including this case (Table 1) . AKI appeared 7.5 ± 6.9 weeks (range 2-20) after introducing the offending drug. The average baseline SCr was (102.08 ± 35.2; range 62.5-149.6 µmol/L) obtained 7.5 ± 4.6 (range 0.5-16) months before the onset of FI-AIN. Fifty percent of patients showed proteinuria (0.3-19.7 g/24 h) associated with microscopic haematuria (12.5%) and leukocyturia (12.5%). The highest SCr reached between 135.52 and 824.56 µmol/L with a mean of 425.04 ± 243.76 µmol/L. Two patients (12.5%) required several sessions of haemodialysis [9] . Thirty-one percent (5/16) presented the classical triad of drug-induced AIN: fever, maculopapular rash and eosinophilia. The renal biopsy was obtained in 14 out of the 16 patients. In all cases, a diffuse inflammatory infiltrate composed of lymphocytes, eosinophils, monocytes and plasma cells invading the interstitial compartment was observed. Fluindione was withdrawn in all patients. Eleven patients (68.75%) were treated with steroids. Steroid doses and the duration of treatment were not uniform. The most common scheme consisted of oral prednisone (0.5-1 mg/kg/day) tapering off over 8-12 weeks. Intravenous pulses of methylprednisolone (250-500 mg daily for 3 days) were occasionally used. In 3 out of these 11 steroid-treated patients (27.3%), SCr never reached baseline values. The five patients who did not receive steroids had a complete recovery of baseline renal function 10 days to 3 weeks after withdrawal of the offending drug. However, the largest study to date by González et al. demonstrated the beneficial effects of steroids for the treatment of drug-induced AIN, especially when initiated soon after withdrawal of the offending agent [1] .
Teaching point
Fluindione must be considered amongst drugs that induce AIN.
